Smoldering multiple myeloma: prevalence and current evidence guiding treatment decisions

Agnieszka Blum, Despina Bazou, Peter O’Gorman Department of Hematology, Mater Misericordiae University Hospital, Dublin, UK Abstract: Smoldering multiple myeloma (SMM) is an asymptomatic plasma cell proliferative disorder associated with risk of progression to symptomatic multiple myeloma...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Blum A, Bazou D, O'Gorman P
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://doaj.org/article/5ba3e1320cb1480eaabafb1d21a824b7
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:5ba3e1320cb1480eaabafb1d21a824b7
record_format dspace
spelling oai:doaj.org-article:5ba3e1320cb1480eaabafb1d21a824b72021-12-02T06:25:36ZSmoldering multiple myeloma: prevalence and current evidence guiding treatment decisions1179-9889https://doaj.org/article/5ba3e1320cb1480eaabafb1d21a824b72018-04-01T00:00:00Zhttps://www.dovepress.com/smoldering-multiple-myeloma-prevalence-and-current-evidence-guiding-tr-peer-reviewed-article-BLCTThttps://doaj.org/toc/1179-9889Agnieszka Blum, Despina Bazou, Peter O’Gorman Department of Hematology, Mater Misericordiae University Hospital, Dublin, UK Abstract: Smoldering multiple myeloma (SMM) is an asymptomatic plasma cell proliferative disorder associated with risk of progression to symptomatic multiple myeloma (MM) or amyloidosis. In comparison to monoclonal gammopathy of undetermined significance (MGUS), SMM has a much higher risk of progression to MM. Thanks to advances in our understanding of the risk factors, the subset of patients with ultra-high risk of progression to MM (80%–90% at 2 years) has been identified. The revision of the diagnostic criteria resulted in changes in the management of this cohort of patients. In contrast to the management guidelines for MGUS patients, SMM patients need to be studied more intensively in order to identify biomarkers necessary for accurate risk stratification. In this review, we focus on the risk of progression from SMM to MM, as well as the influence of early treatment on overall survival, time to progression and quality of life. Keywords: smoldering multiple myeloma, risk factor, biomarker, genomic aberrations, glycan analysisBlum ABazou DO'Gorman PDove Medical PressarticleSmoldering multiple myelomarisk factorbiomarkergenomic aberrationsDiseases of the blood and blood-forming organsRC633-647.5ENBlood and Lymphatic Cancer: Targets and Therapy, Vol Volume 8, Pp 21-31 (2018)
institution DOAJ
collection DOAJ
language EN
topic Smoldering multiple myeloma
risk factor
biomarker
genomic aberrations
Diseases of the blood and blood-forming organs
RC633-647.5
spellingShingle Smoldering multiple myeloma
risk factor
biomarker
genomic aberrations
Diseases of the blood and blood-forming organs
RC633-647.5
Blum A
Bazou D
O'Gorman P
Smoldering multiple myeloma: prevalence and current evidence guiding treatment decisions
description Agnieszka Blum, Despina Bazou, Peter O’Gorman Department of Hematology, Mater Misericordiae University Hospital, Dublin, UK Abstract: Smoldering multiple myeloma (SMM) is an asymptomatic plasma cell proliferative disorder associated with risk of progression to symptomatic multiple myeloma (MM) or amyloidosis. In comparison to monoclonal gammopathy of undetermined significance (MGUS), SMM has a much higher risk of progression to MM. Thanks to advances in our understanding of the risk factors, the subset of patients with ultra-high risk of progression to MM (80%–90% at 2 years) has been identified. The revision of the diagnostic criteria resulted in changes in the management of this cohort of patients. In contrast to the management guidelines for MGUS patients, SMM patients need to be studied more intensively in order to identify biomarkers necessary for accurate risk stratification. In this review, we focus on the risk of progression from SMM to MM, as well as the influence of early treatment on overall survival, time to progression and quality of life. Keywords: smoldering multiple myeloma, risk factor, biomarker, genomic aberrations, glycan analysis
format article
author Blum A
Bazou D
O'Gorman P
author_facet Blum A
Bazou D
O'Gorman P
author_sort Blum A
title Smoldering multiple myeloma: prevalence and current evidence guiding treatment decisions
title_short Smoldering multiple myeloma: prevalence and current evidence guiding treatment decisions
title_full Smoldering multiple myeloma: prevalence and current evidence guiding treatment decisions
title_fullStr Smoldering multiple myeloma: prevalence and current evidence guiding treatment decisions
title_full_unstemmed Smoldering multiple myeloma: prevalence and current evidence guiding treatment decisions
title_sort smoldering multiple myeloma: prevalence and current evidence guiding treatment decisions
publisher Dove Medical Press
publishDate 2018
url https://doaj.org/article/5ba3e1320cb1480eaabafb1d21a824b7
work_keys_str_mv AT bluma smolderingmultiplemyelomaprevalenceandcurrentevidenceguidingtreatmentdecisions
AT bazoud smolderingmultiplemyelomaprevalenceandcurrentevidenceguidingtreatmentdecisions
AT ogormanp smolderingmultiplemyelomaprevalenceandcurrentevidenceguidingtreatmentdecisions
_version_ 1718399933470474240